Your browser doesn't support javascript.
loading
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
van Huizen, Astrid M; Menting, Stef P; Gyulai, Rolland; Iversen, Lars; van der Kraaij, Gayle E; Middelkamp-Hup, Maritza A; Warren, Richard B; Spuls, Phyllis I; Schejtman, Adrián A; Egeberg, Alexander; Firooz, Alireza; Kumar, Alur S; Oakley, Amanda; Foulkes, Amy; Ramos, Andrea Machado Coelho; Fougerousse, Anne-Claire; Carija, Antoanela; Akman-Karakas, Ayse; Horváth, Barbara; Fábos, Béata; Matlock, Benjamin Hidalgo; Claréus, Birgitta Wilson; Castro, Carla; Ferrándiz, Carlos; Correa, Carolina Cortés; Marchesi, Carolina; Goujon, Catherine; Gonzalez, Cesar; Maldonado-García, César; Hong, Chih-Ho; Griffiths, Christopher E M; Vestergaard, Christian; Echeverría, Christina Mariela; de la Cruz, Claudia; Conrad, Curdin; Törocsik, Dániel; Drvar, Daniela Ledic; Balak, Deepak; Jullien, Denis; Appelen, Diebrecht; Kim, Dong Hyun; de Jong, Elke M G J; El Gamal, Emad; Laffitte, Emmanuel; Mahé, Emmanuel; Sonkoly, Enikö; Colombo, Erika Páez; Vilarrasa, Eva; Willaert, Fabienne; Novoa, Farah D.
Afiliação
  • van Huizen AM; Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
  • Menting SP; Department of Dermatology, OLVG, Amsterdam, the Netherlands.
  • Gyulai R; Department of Dermatology, University of Pécs, Medical School, Venerology and Oncodermatology, Pécs, Hungary.
  • Iversen L; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
  • van der Kraaij GE; Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
  • Middelkamp-Hup MA; Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
  • Warren RB; The Dermatology Centre, Salford Royal NHS Foundation Trust, The Manchester NIHR Biomedical Research Centre, United Kingdom.
  • Spuls PI; Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
  • Schejtman AA; Centro Dermatológico Schejtman, Provincia de Buenos Aires, Argentina.
  • Egeberg A; Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
  • Firooz A; Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
  • Kumar AS; Apollo Hospital, Secunderabad, Telangana, India.
  • Oakley A; Waikato District Health Board, University of Auckland, Auckland, New Zealand.
  • Foulkes A; The Dermatology Centre, Salford Royal NHS Foundation Trust, The Manchester NIHR Biomedical Research Centre, United Kingdom.
  • Ramos AMC; Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Fougerousse AC; Military Teaching Hospital Begin, Saint Mandé, France.
  • Carija A; School of Medicine, University of Split, University Hospital Centre Split, Croatia.
  • Akman-Karakas A; Department of Dermatology and Venerology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Horváth B; Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Fábos B; Department of Dermatology, Teaching Hospital Kaposvar, Kaposvar, Hungary.
  • Matlock BH; University of Costa Rica/Hospital Nacional de Niños, San Pedro Montes de Oca, San Jose Province, Costa Rica.
  • Claréus BW; Psoriasis Treatment Wards, Stockholm, Sweden.
  • Castro C; Dermatologist Hospital Universitario Austral, Buenos Aires, Argentina.
  • Ferrándiz C; Department of Dermatology, Hospital universitario Germans Trias i Pujol, Universidad Autónoma de Barcelona, Barcelona, Spain.
  • Correa CC; Dermatology Service of La Samaritana University Hospital, Bogotá, Colombia.
  • Marchesi C; Pontificia Universidad Javeriana/National University of Colombia, Bogotá, Colombia.
  • Goujon C; Proderma, Clínica de la piel, San Juan, Argentina.
  • Gonzalez C; Department of Immunology and Clinical Allergology, Lyon sud Hospital, Saint-Genis-Laval, France.
  • Maldonado-García C; Private practice, Bogotá, Colombia.
  • Hong CH; Centro Dermatologico "Dr. Ladislao de la Pascua," Mexico City, Mexico.
  • Griffiths CEM; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Vestergaard C; The Dermatology Centre, Salford Royal NHS Foundation Trust, The Manchester NIHR Biomedical Research Centre, United Kingdom.
  • Echeverría CM; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
  • de la Cruz C; Instituto de Rehabilitación Psicofísica, IREP, Buenos Aires, Argentina.
  • Conrad C; Clinica Dermacross, Santiago, Chile.
  • Törocsik D; Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
  • Drvar DL; Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Balak D; Department of Dermatology and Venereology, University Hospital Centre Zagreb, School of Medicine University of Zagreb, Croatia.
  • Jullien D; Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
  • Appelen D; Hospices Civils de Lyon, Hôpital E. Herriot, Service de Dermatologie, Lyon, France.
  • Kim DH; Radboud University Medical Center, Nijmegen, the Netherlands.
  • de Jong EMGJ; Department of Dermatology, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam, Republic of Korea.
  • El Gamal E; Radboud University Medical Center, Nijmegen, the Netherlands.
  • Laffitte E; Damietta Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Mahé E; Department of Dermatology, University Hospital of Geneva, Geneva, Switzerland.
  • Sonkoly E; Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France.
  • Colombo EP; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Vilarrasa E; Hospital Vargas de Caracas, Venezuela.
  • Willaert F; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Novoa FD; Hôpital ERASME, Université Libre de Bruxelles, Anderlecht, Belgium.
JAMA Dermatol ; 158(5): 561-572, 2022 05 01.
Article em En | MEDLINE | ID: mdl-35353175
ABSTRACT
Importance A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide.

Objective:

To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. Design, Setting, and

Participants:

Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). Main Outcomes and

Measures:

In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree.

Results:

Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. Conclusions and Relevance In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Metotrexato Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Metotrexato Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article